CN114126663A - Nk细胞定向的嵌合蛋白 - Google Patents

Nk细胞定向的嵌合蛋白 Download PDF

Info

Publication number
CN114126663A
CN114126663A CN202080051217.9A CN202080051217A CN114126663A CN 114126663 A CN114126663 A CN 114126663A CN 202080051217 A CN202080051217 A CN 202080051217A CN 114126663 A CN114126663 A CN 114126663A
Authority
CN
China
Prior art keywords
chimeric protein
domain
cells
nkg2a
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051217.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·施赖伯
C·舒普特林
G·弗罗姆
S·达西瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CN114126663A publication Critical patent/CN114126663A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080051217.9A 2019-05-16 2020-05-15 Nk细胞定向的嵌合蛋白 Pending CN114126663A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848915P 2019-05-16 2019-05-16
US62/848,915 2019-05-16
PCT/US2020/033169 WO2020232365A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Publications (1)

Publication Number Publication Date
CN114126663A true CN114126663A (zh) 2022-03-01

Family

ID=73289381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051217.9A Pending CN114126663A (zh) 2019-05-16 2020-05-15 Nk细胞定向的嵌合蛋白

Country Status (7)

Country Link
US (2) US20200399344A1 (https=)
EP (1) EP3969058A4 (https=)
JP (1) JP2022532430A (https=)
CN (1) CN114126663A (https=)
AU (1) AU2020276296A1 (https=)
CA (1) CA3140055A1 (https=)
WO (1) WO2020232365A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853905A (zh) * 2022-04-14 2022-08-05 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524301A (ja) * 2021-07-02 2024-07-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用
WO2024073513A2 (en) * 2022-09-27 2024-04-04 Affini-T Therapeutics, Inc. Chimeric receptors comprising interleukin 7 receptor (il7r) domains
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281035A1 (en) * 2006-06-22 2009-11-12 Novo Nordisk A/S Soluble Heterodimeric Receptors and Uses Thereof
US20170008951A1 (en) * 2012-01-27 2017-01-12 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US20180134766A1 (en) * 2016-09-27 2018-05-17 Epicentrx, Inc. Immunomodulatory fusion proteins
CN108350055A (zh) * 2015-10-01 2018-07-31 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281035A1 (en) * 2006-06-22 2009-11-12 Novo Nordisk A/S Soluble Heterodimeric Receptors and Uses Thereof
US20170008951A1 (en) * 2012-01-27 2017-01-12 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CN108350055A (zh) * 2015-10-01 2018-07-31 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
US20180326008A1 (en) * 2015-10-01 2018-11-15 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US20180134766A1 (en) * 2016-09-27 2018-05-17 Epicentrx, Inc. Immunomodulatory fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853905A (zh) * 2022-04-14 2022-08-05 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案

Also Published As

Publication number Publication date
EP3969058A1 (en) 2022-03-23
CA3140055A1 (en) 2020-11-19
US20200399344A1 (en) 2020-12-24
JP2022532430A (ja) 2022-07-14
EP3969058A4 (en) 2023-06-28
US20230045794A1 (en) 2023-02-16
WO2020232365A1 (en) 2020-11-19
AU2020276296A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CN110381983B (zh) 基于tigit和light的嵌合蛋白
US20230045794A1 (en) Nk cell-directed chimeric proteins
KR20180051651A (ko) 비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법
CN113747947A (zh) 组合疗法
CN112771067A (zh) 包含基于SIRPα的嵌合蛋白的组合疗法
CN110381974A (zh) 基于csf1r的嵌合蛋白
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
CN112888711A (zh) 基于flt3l的嵌合蛋白
US20240141014A1 (en) Mutant pd-1 extracellular domains
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
KR20240118207A (ko) Sirp1a - 및 cd40l-기반 키메라 단백질
CN112912384A (zh) 组合疗法
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
CN112888706A (zh) 包含基于tim-3的嵌合蛋白的组合疗法
RU2792239C2 (ru) Химерные белки на основе csf1r
WO2024123890A1 (en) Methods of using light-based chimeric proteins
CN117355336A (zh) 基于SIRP α的嵌合蛋白的联合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301

WD01 Invention patent application deemed withdrawn after publication